摘要
目的研究抑癌基nm2 3 H1及TGF β在前列腺癌组织中的表达与意义。 方法采用鼠抗人nm2 3 H1及TGF β单克隆抗体及免疫组织化学SABC法。 结果在 40例前列腺癌组织标本中 ,nm2 3 H1在高、中、低分化前列腺癌组织中的阳性表达率分别为 70 % (7/ 10 )、6 8 75 % (11/ 16 )、2 1 42 %(3/ 14) ;临床分期阳性率分别为T16 6 7% (10 / 15 )、T2 6 3 36 % (7/ 11)、T333 3% (2 / 6 )、T4 2 5 % (2 / 8)。TGF β在高、中、低分化前列腺癌组织中的阳性表达率分别为 30 % (3/ 10 )、31 2 5 % (5 / 16 )、71 42 % (10 /14) ;临床分期阳性率分别为T14 0 % (6 / 15 )、T2 45 5 % (5 / 11)、T35 0 % (3/ 6 )、T4 5 0 % (4/ 8)。nm2 3 H1在高、中分化前列腺癌组织中的表达强于在低分化前列腺癌组织中的表达 (P <0 0 1) ,T1、T2 期阳性表达强于T3、T4 期 (P <0 0 1)。TGF β在高、中分化前列腺癌组织中的表达弱于低分化前列腺癌组织 (P <0 0 1) ,而其在不同临床分期的表达差异无显著意义 (P >0 0 5 )。结论抑癌基因nm2 3 H1表达与前列腺癌分化程度及临床分期呈负相关 ;TGF β表达与前列腺癌病理分化呈正相关 ,而与其临床分期无关。因而借助nm2 3 H1与TGF
Objective To study the expression and significance of TGF β and tumor suppressor gene nm23 H 1 and TGF β in prostate cancer. Methods streptavidin Biotin peroxidase Complex(SABC) methods, Monoclonal antibody against TGF β and nm23 H 1 protein on archival material were employed. Results TGF β protein was detected in 18 out of 40 cases of prostate cancer, and in 26 cases of well and moderately differentiated prostate cancer positive rate was weak than that of 14 cases of poorly differentiated prostate cancer( P <0.01), there were no significantly relation between TGF β expression and prostate cancer clinical stage ( P >0.05). nm23 H 1 protein was detected in 21 out of 40 cases of prostate cancer, and in 26 cases of well and moderately differentiated prostate cancer positive rate was higher than that of 14 cases of poorly differentiated prostate cancer ( P <0.01), 26 cases of clinical T 1 and T 2 stage prostate cancer showed stronger expression than that of T 3 and T 4 stages cancer( P <0.01). Conclusion Expression of nm23 H 1 and TGF β may help identification of prostate cancer's pathologic grade and predict the prognosis.
出处
《贵州医药》
CAS
2001年第10期871-873,F003,共4页
Guizhou Medical Journal